CPIG
NBIX icon

Chicago Partners Investment Group’s Neurocrine Biosciences NBIX Stock Holding History

Chicago Partners Investment Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
8,472
+1,083
+15% +$161K 0.03% 485
2026
Q1 		$969K Buy
7,389
+2,030
+38% +$269K 0.02% 567
2025
Q4 		$730K Buy
5,359
+1,793
+50% +$260K 0.02% 571
2025
Q3 		$526K Buy
+3,566
New +$483K 0.01% 678
2025
Q1 		– Sell
-1,836
Closed -$255K – 974
2024
Q4 		$255K Buy
+1,836
New +$227K 0.01% 725

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Chicago Partners Investment Group's NBIX Position: Q2 2026 in Review

Chicago Partners Investment Group increased its Neurocrine Biosciences (NBIX) stake by 15% in Q2 2026, buying an estimated $161K and bringing the position to 8,472 shares worth $1.48M. The position accounts for 0.03% of the portfolio, ranked #485.

Chicago Partners Investment Group first reported a position in NBIX in Q4 2024 and has held it in 5 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Chicago Partners Investment Group held 8,472 shares of Neurocrine Biosciences worth $1.48M as of Q2 2026.
  • Chicago Partners Investment Group bought 1,083 Neurocrine Biosciences shares in Q2 2026, an estimated $161K.
  • Neurocrine Biosciences made up 0.03% of Chicago Partners Investment Group's portfolio in Q2 2026, its #485 holding.
  • Chicago Partners Investment Group first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 5 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.